Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
暂无分享，去创建一个
A. Pettitt | C. Fegan | C. Yap | C. Dearden | A. Schuh | R. Jackson | N. Kalakonda | S. Coupland | Ke Lin | A. Duncombe | J. Dodd | S. Marshall | P. Hillmen | C. Fox | B. Kennedy | R. Walewska | M. Oates | H. McCarthy | S. Cicconi | A. Bloor | U. Khan | M. Bickerstaff | G. Menon | F. Polydoros | S. Carruthers | Michael Stackpoole